Metrics as of 10/14/2026, 07:08 PM (Berlin time), refresh in progress.
MannKind Stock
MannKind Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael E. Castagna
- Employees
- 592
- Market cap
- $977 M
- IPO
- 28/07/2004
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled…
MannKind stock: price history
1D
-4.7%
1W
-7.6%
1M
-14.4%
6M
+7.0%
YTD
-46.4%
1Y
-43.2%
2Y
-54.8%
5Y
-40.3%
10Y
+32.2%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~31% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about MannKind
Analyst assessment of MannKind
PRICE TARGET LOW
US$7.00
CONSENSUS
US$10.00
MEDIAN
US$10.00
PRICE TARGET HIGH
US$13.00
0
STRONG BUY
11
BUY
3
HOLD
7
SELL
0
STRONG SELL
21
TOTAL · Buy
As of: 07/10/2026
MannKind stock metrics
P/E
-21.65
P/B
-13.9
EV/EBITDA
41.45
RETURN ON EQUITY
28.3%
NET MARGIN
-17.4%
DEBT/EQUITY
-4.92
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
94.9%
FLOAT SHARES
303,095,560
AVG. DAILY VOLUME (30D)
4,980,750
Insider transactions (SEC)
Binder Steven B.
Binder Steven B.
Binder Steven B.
Binder Steven B.
Binder Steven B.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about MannKind stock
What does MannKind do?
MannKind Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael E. Castagna, the company employs around 592 people.
The IPO was on 28/07/2004; the stock trades on NASDAQ under the ticker MNKD.
What do analysts say about MannKind stock?
21 analysts rate the stock, the consensus is Buy (as of 07/10/2026).
The average price target is US$10.00, ranging from US$7.00 to US$13.00, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
When does MannKind report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 31% stronger than usual.
Does MannKind pay a dividend?
No, MannKind currently does not pay a dividend.
Which stocks are comparable to MannKind?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get MannKind stock analyzed?
Clicking "Analyze stock" lets five strategies assess MannKind against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.